XML 97 R84.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenue recognition Recenue recognition - Roche and SMA Foundation (Details) |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Dec. 31, 2018 USD ($) | Oct. 31, 2017 USD ($) | Nov. 30, 2014 USD ($) | Jan. 31, 2014 USD ($) | Aug. 31, 2013 USD ($) | Nov. 30, 2011 USD ($) compound | Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Sep. 30, 2017 USD ($) | Jun. 30, 2017 USD ($) | Mar. 31, 2017 USD ($) | Dec. 31, 2018 USD ($) deliverable | Dec. 31, 2017 USD ($) deliverable | Dec. 31, 2016 USD ($)
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net Product Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 263,005,000 |  |
Additions |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,417,000 |  |
Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 264,734,000 | $ 194,392,000 |
Net product revenue |  |  |  |  |  |  | $ 85,833,000 | $ 53,021,000 | $ 68,170,000 | $ 55,981,000 | $ 57,953,000 | $ 41,780,000 | $ 47,891,000 | $ 26,442,000 | 264,734,000 | 194,392,000 | $ 82,705,000
Licensing And Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligations satisfied in current period |  | $ 20,000,000 | $ 10,000,000 | $ 7,500,000 | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Additions |  |  |  |  |  | $ 30,000,000 |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200,000 | $ 20,300,000 | 400,000
Grant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net product revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  | $ 900,000
Collaborative Arrangement [Member] | Roche And Sma Foundation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements Number of Compounds in Preclinical Development | compound |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements Number of Significant Deliverables | deliverable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |
Collaboration And Discovery Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements Number of Significant Deliverables | deliverable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |
Research And Development Event Milestones | Licensing And Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition, Milestone, Potential Achievements | $ 87,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 135,000,000 |  |
Research And Development Event Milestones | Early Stage Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition, Milestone, Potential Achievements |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 143,000,000 |  |
Potential net sales milestones | Licensing And Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition, Milestone, Potential Achievements | $ 325,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 325,000,000 |  |
Potential net sales milestones | Early Stage Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition, Milestone, Potential Achievements |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 252,000,000 |  |
Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of Grant Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 years |  |
Minimum | Collaboration And Discovery Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements Research Period for Applying Discovery Technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  |
Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of Grant Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |
Maximum | Collaboration And Discovery Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements Research Period for Applying Discovery Technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 years |  |
United States |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net Product Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 92,000,000 |  |
Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 93,694,000 | $ 49,155,000 |
Non-US |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net Product Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 171,000,000 |  |
Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 171,040,000 | $ 145,237,000 |

X
- Definition Represents the number of compounds included in preclinical development. + References No definition available. + Details
Name: | ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment
Namespace Prefix: | ptct_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of significant deliverables under a contractual agreement. + References No definition available. + Details
Name: | ptct_CollaborativeArrangementsNumberOfSignificantDeliverables
Namespace Prefix: | ptct_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the research period for applying discovery technology. + References No definition available. + Details
Name: | ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology
Namespace Prefix: | ptct_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract with Customer, Liability, Increase from Cash Receipts + References No definition available. + Details
Name: | ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of revenue earned from product sales during the reporting period. + References No definition available. + Details
Name: | ptct_NetProductSales
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Recognition, Milestone, Potential Achievements + References No definition available. + Details
Name: | ptct_RevenueRecognitionMilestonePotentialAchievements
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the term of the grant program. + References No definition available. + Details
Name: | ptct_TermOfGrantProgram
Namespace Prefix: | ptct_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_RocheAndSmaFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptct_CollaborationAndDiscoveryAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ptct_MilestoneAxis=ptct_ResearchAndDevelopmentEventMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ptct_EarlyStageCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ptct_MilestoneAxis=ptct_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |